Advisor Group Holdings, Inc. Adverum Biotechnologies, Inc. Transaction History

Advisor Group Holdings, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$0.75 - $1.26 $8,349 - $14,027	11,133 Added 12.46%	100,500 $75,000
Q3 2023 Nov 13, 2023	BUY	$1.5 - $2.33 $39,325 - $61,085	26,217 Added 41.52%	89,367 $134,000
Q2 2023 Aug 10, 2023	SELL	$0.68 - $1.59 $20,400 - $47,700	-30,000 Reduced 32.21%	63,150 $100,000
Q1 2023 May 12, 2023	BUY	$0.62 - $0.85 $55,800 - $76,500	90,000 Added 2857.14%	93,150 $67,000
Q4 2022 Feb 10, 2023	BUY	$0.54 - $10.3 $621 - $11,845	1,150 Added 57.5%	3,150 $1,000
Q3 2021 Nov 05, 2021	SELL	$2.08 - $3.6 $832 - $1,440	-400 Reduced 16.67%	2,000 $4,000
Q1 2020 May 18, 2020	BUY	$7.98 - $16.32 $19,152 - $39,168	2,400 New	2,400 $24,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.